Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
QNTM.CN
STRONG SELLREMOVEQuantum BioPharma Ltd. · Healthcare · Canada · $45M · Avg Vol: $77K/d
Quantum BioPharma is a micro-cap biotech with highly speculative operations and weak financial health. It fails all quality and cash flow metrics under the Buffett and Smith lenses.
COMPANY DESCRIPTION
Quantum BioPharma Ltd. is a biotechnology company focused on developing innovative biopharmaceutical products and diagnostic solutions. The company leverages advanced research in natural compounds and synthetic formulations to target chronic diseases and neurological disorders. Quantum BioPharma aims to build a robust pipeline of intellectual property through strategic clinical trials and academic partnerships.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR |
|---|---|---|---|---|---|---|
| Revenue | — | 0 | 0 | 0 | 0 | — |
| EPS | — | -3.67 | -2.83 | -4.72 | -8.20 | — |
| Shares | — | 6.4M | 6.4M | 6.4M | 3.9M | -39.2% |
| Debt | — | 0.5M | 0.3M | 0.8M | 1.9M | 53.7% |
| Equity | — | 30.5M | 13.2M | 11.5M | 6.9M | -39.0% |
| Op CF | — | -28.3M | -10.8M | -6.9M | -8.2M | — |
| Inv CF | — | 12.1M | -0.3M | -1.5M | -2.0M | — |
| Fin CF | — | -2.1M | -3.1M | 11.6M | 6.1M | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of QNTM.CN are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| QNTM.CN | Quantum BioPharma Ltd.(you) | $45M | 2 | STRONG SELL |
| MDNA.TO | Medicenna Therapeutics Corp. | $27M | 1 | STRONG SELL |
| EDSA | Edesa Biotech, Inc. | $61M | 17 | STRONG SELL |
| ENGN | enGene Therapeutics Inc. | $114M | 8 | STRONG SELL |
| MIST | Milestone Pharmaceuticals Inc. | $161M | 1 | STRONG SELL |
| MSLE | Satellos Bioscience Inc. | $119M | 10 | STRONG SELL |
| PMN | ProMIS Neurosciences, Inc. | $97M | 15 | STRONG SELL |
| OBI.L | Ondine Biomedical Inc. | $101M | 20 | SELL |
| NGEN | NervGen Pharma Corp. | $244M | 1 | STRONG SELL |
| HELP | Cybin D/B/A Helus Pharma | $245M | 6 | STRONG SELL |
Peer medians: ROE -42.2% · P/E 14.3x · Gross margin 35.6%